Brexogen

Focus: Brexogen is a Seoul-based biotech company specializing in exosome therapeutics with a focus on immunology applications. The company is in early-stage development with a nascent pipeline.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Brexogen

AI assessmentNot Hiring

No open roles listed right now. Follow Brexogen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BxC-I17e

Atopic Dermatitis

Phase 1

Clinical Trials (1)

NCT06055374A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Phase 1

Help build intelligence for Brexogen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in emerging exosome therapeutic modality with potential to define a new category in immunology
Early-stage biotech environment offers direct impact on drug development and rapid skill acquisition across functions
Seoul location provides access to growing Korean biotech ecosystem with lower cost of living than Western hubs

Watch Out For

No active job openings currently listed suggests minimal hiring or early dormancy stage
Pre-revenue status with unknown funding creates significant cash runway and stability risk
Only one program (BxC-I17e) in Phase 1 with no Phase 2/3 catalysts on horizon limits near-term visibility

Generated by Claude from Brexogen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BxC-I17e

Atopic Dermatitis

Phase 1

Clinical Trials (1)

NCT06055361A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Phase 1

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Immunology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Immunology

2 pipeline

Marketed

Pipeline